ElexoPharm GmbH Receives ETB Grant
News Oct 18, 2012
Recently, a EuroTransBio grant of €1.5 million has been awarded to a transnational consortium including ElexoPharm GmbH by the European Collaborative ETB program.
The project is a collaboration of ElexoPharm GmbH with SomantiX BV (Bilthoven, The Netherlands), VU University Medical Center (Amsterdam, The Netherlands), Saarland University (Saarbrücken, Germany) and PharmBioTec GmbH (Saarbrücken, Germany).
This subsidy is awarded for a period of three years and will allow the development of low molecular weight inhibitors of angiogenesis in colorectal cancer.
At ElexoPharm, lead finding and lead optimization based on molecular modelling, design and synthesis of biological active compounds, will be performed.
"ElexoPharm is very proud to have received this prestigious transnational grant to develop medicines to treat this disease of high medical need. It is a further recognition of the excellent drug discovery capabilities of our growing company", states Axel Koch, Managing Director of ElexoPharm.
Diabetic Ketoacidosis Assay Collaboration Between Ortho Clinical Diagnostics and EKF DiagnosticsNews
EKF’s Beta-Hydroxybutyrate LiquiColor® Assay for detection of predominant ketone body now available on Ortho’s VITROS® 4600 Chemistry System and VITROS® 5600 Integrated System.READ MORE
Key Cancer-Linked Proteins Thought to be ‘Undruggable’ Until NowNews
A new study published in Nature, conducted by an alliance between industry and academia involving the University of Liverpool, highlights a new approach to targeting key cancer-linked proteins, thought to be ‘undruggable’.READ MORE
Researchers Reveal How Superbug Secretes It’s ToxinNews
Monash University’s Biomedicine Discovery Institute (BDI) researchers have created the first high-resolution structure depicting a crucial part of the ‘superbug’ Pseudomonas aeruginosa. The image identifies the ‘nanomachine’ used by the highly virulent bacteria to secrete toxins, pointing the way for drug design targeting this.READ MORE